Clinical Trial VICCNEU1216


An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF with Adjuvant Temozolomide in Patients with Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma

Principal Investigator(s)

Reid Thompson


  • Protocol No. VICCNEU1216
  • Open Date: 10/02/2012
  • Staging: Phase III
  • Age Group: Adults
  • Scope: International
  • Objective: The primary objective of the study is to confirm that the addition of rindopepimut/GM-CSF to adjuvant temozolomide improves overall survival in patients with newly diagnosed EGFRvIII positive glioblastoma who have undergone gross-total resection.
  • Disease Sites: Neuro-Oncology
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: GM-CSF; Rindopepimut; TMZ; Temodar; Temozolomide
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01480479
  • Secondary Protocol No: CDX110-04



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.